Get the Stockscreener App
0.3041
3.18%
-0.01
Intensity Therapeutics Inc stock is traded at $0.3041, with a volume of 2.15M.
It is down -3.18% in the last 24 hours and down -0.94% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$0.3141
Open:
$0.3025
24h Volume:
2.15M
Relative Volume:
0.60
Market Cap:
$14.31M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-0.2574
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
+3.19%
1M Performance:
-0.94%
6M Performance:
-86.36%
1Y Performance:
-92.87%
1-Day Range:
$0.2977
$0.3132
1-Week Range:
$0.2783
$0.32
52-Week Range:
$0.1853
$4.35
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.3041 | 14.31M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc Stock (INTS) Latest News
How to escape a deep drawdown in Intensity Therapeutics Inc.Quarterly Profit Review & Detailed Earnings Play Alerts - Newser
Benchmark lowers Intensity Therapeutics stock price target to $1.50 on dilution - Investing.com
Building trade automation scripts for Intensity Therapeutics Inc.July 2025 Recap & AI Enhanced Trading Alerts - Newser
Can Intensity Therapeutics Inc. hit a new high this monthWeekly Trade Recap & Risk Controlled Swing Trade Alerts - Newser
Can trapped investors hope for a rebound in Intensity Therapeutics Inc.July 2025 Analyst Calls & Scalable Portfolio Growth Ideas - Newser
Multi asset correlation models including Intensity Therapeutics Inc.Portfolio Performance Summary & Fast Moving Trade Plans - Newser
Applying Elliott Wave Theory to Intensity Therapeutics Inc.Earnings Risk Summary & Smart Investment Allocation Insights - Newser
Momentum divergence signals in Intensity Therapeutics Inc. chartPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
Real time scanner hits for Intensity Therapeutics Inc. explainedJuly 2025 Review & Reliable Price Breakout Alerts - Newser
Is now a turning point for Intensity Therapeutics Inc.2025 Market Trends & Real-Time Buy Zone Alerts - Newser
How to interpret RSI for Intensity Therapeutics Inc. stockJuly 2025 PostEarnings & AI Based Buy/Sell Signal Reports - Newser
Detecting price anomalies in Intensity Therapeutics Inc. with AIWeekly Volume Report & High Yield Equity Trading Tips - Newser
Can a trend reversal in Intensity Therapeutics Inc. lead to recoveryMarket Volume Report & Real-Time Chart Breakout Alerts - Newser
Detecting support and resistance levels for Intensity Therapeutics Inc.July 2025 Rallies & Target Return Focused Stock Picks - Newser
Why is Intensity Therapeutics Inc. stock going downWatch List & Real-Time Stock Price Movement Reports - mustnews.co.kr
Sentiment analysis tools applied to Intensity Therapeutics Inc.July 2025 Gainers & Long-Term Safe Investment Ideas - Newser
How to recover losses in Intensity Therapeutics Inc. stockLong Setup & Reliable Intraday Trade Alerts - Newser
Using data filters to optimize entry into Intensity Therapeutics Inc.2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Can momentum traders help lift Intensity Therapeutics Inc.Trade Entry Summary & Reliable Volume Spike Trade Alerts - Newser
Technical signs of recovery in Intensity Therapeutics Inc.Share Buyback & Capital Efficient Trading Techniques - Newser
Using Python tools to backtest Intensity Therapeutics Inc. strategiesMarket Performance Report & Growth Focused Investment Plans - Newser
How Resilient Is Intensity Therapeutics Inc. Stock During Economic DownturnsJuly 2025 EndofMonth & Free Growth Oriented Trading Recommendations - Newser
Intensity (INTS) Q2 Net Loss Drops 50% - AOL.com
Intensity Therapeutics regains Nasdaq compliance - MSN
Analyzing recovery setups for Intensity Therapeutics Inc. investors2025 Risk Factors & Daily Chart Pattern Signals - Newser
Intensity Therapeutics Reports Reduced Losses and Clinical Progress - TipRanks
Intensity Therapeutics Inc (INTS) Stock: Navigating a Year of Volatility - investchronicle.com
Intensity Therapeutics shares rise 5.10% premarket after regaining compliance with Nasdaq's minimum Stockholders' Equity Requirement. - AInvest
Shelton-based biotech regains Nasdaq compliance - Hartford Business Journal
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):